Ticagrelor Use may Increase the Risk of Atorvastatin-Related Rhabdomyolysis

Yilmaz B., Yilmaz A., Ersan S., Alp A., GÜLLE S.

TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL, vol.26, no.3, pp.354-356, 2017 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.5262/tndt.2017.1003.19
  • Journal Name: TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.354-356
  • Keywords: Ticagrelor, Rhabdomyolysis, Atorvastatin, RENAL-FUNCTION
  • Dokuz Eylül University Affiliated: No

Abstract

Ticagrelor is an antiplatelet aggregation inhibitor used after acute coronary syndrome. It is metabolized by the cytochrome P450 enzyme system in the liver, like the statins. Using these two agents together may result in rhabdomyolysis because of the rising serum atorvastatin level. Due to the increasing use of ticagrelor in the recent period, rhabdomyolysis has been seen as a side effect. We present a case of severe rhabdomyolysis possibly due to increased level of atorvastatin, in a patient using ticagrelor.